rs1555436118
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_020778.5(ALPK3):c.4688G>A(p.Trp1563*) variant causes a stop gained change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_020778.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cardiomyopathy, familial hypertrophic 27 Pathogenic:1
- -
Cardiovascular phenotype Pathogenic:1
The p.W1765* pathogenic mutation (also known as c.5294G>A), located in coding exon 12 of the ALPK3 gene, results from a G to A substitution at nucleotide position 5294. This changes the amino acid from a tryptophan to a stop codon within coding exon 12. This alteration was reported as homozygous in a four-year-old subject with hypertrophic cardiomyopathy (HCM) and as heterozygous in the father who was diagnosed with HCM in adulthood (Almomani R et al. J Am Coll Cardiol, 2016 Feb;67:515-25). This alteration has also been reported as homozygous in several family members with dilated cardiomyopathy and hypertrophic cardiomyopathy phenotypes (Al Senaidi K et al. Am J Med Genet A, 2019 07;179:1235-1240). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at